Page 52 - Read Online

Sumani KM, Alder H, Amadori D, Patel T, Nuovo GJ, 102. Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S,
Fishel R, Croce CM. MicroRNA-21 induces resistance to Marubashi S, Tanemura M, Tomokuni A, Takemasa I,
5-fl uorouracil by down-regulating human DNA MutS homolog Umeshita K, Kanto T, Doki Y, Mori M. Circulating
2 (hMSH2). Proc Natl Acad Sci U S A 2010;107:21098-103. microRNA-21 as a novel biomarker for hepatocellular
84. Rossi L, Bonmassar E, Faraoni I. Modifi cation of miR carcinoma. J Hepatol 2012;56:167-75.
gene expression pattern in human colon cancer cells 103. Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, Zhang JF, Shen HB,
following exposure to 5-fl uorouracil in vitro. Pharmacol Res Zhang CY, Zen K. Serum microRNA profi les serve as novel
2007;56:248-53. biomarkers for HBV infection and diagnosis of HBV-positive
85. Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, hepatocarcinoma. Cancer Res 2010;70:9798-807.
Gavin E, Wan Y, Formentini A, Kornmann M, Fodstad O, 104. Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, Fan ST,
Ju J. Mechanism of chemoresistance mediated by miR-140 Poon RT, Gao C, Luk JM. Circulating miR-15b and miR-130b
in human osteosarcoma and colon cancer cells. Oncogene in serum as potential markers for detecting hepatocellular
2009;28:4065-74. carcinoma: A retrospective cohort study. BMJ Open
86. Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, 2012;2:e000825.
Kornmann M, Ju J. Molecular mechanism of chemoresistance 105. Hou W, Bonkovsky HL. Non-coding RNAs in hepatitis
by miR-215 in osteosarcoma and colon cancer cells. Mol C-induced hepatocellular carcinoma: dysregulation and
Cancer 2010;9:96. implications for early detection, diagnosis and therapy. World
87. Mencia N, Selga E, Noe V, Ciudad CJ. Underexpression of J Gastroenterol 2013;19:7836-45.
miR-224 in methotrexate resistant human colon cancer cells. 106. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating
Biochem Pharmacol 2011;82:1572-82. microRNAs as biomarkers for hepatocellular carcinoma.
88. Chai H, Liu M, Tian R, Li X, Tang H. miR-20a targets BNIP2 J Clin Gastroenterol 2011;45:355-60.
and contributes chemotherapeutic resistance in colorectal 107. Hu QY, Jiang H, Su J, Jia YQ. MicroRNAs as biomarkers for
adenocarcinoma SW480 and SW620 cell lines. Acta Biochim hepatocellular carcinoma: a diagnostic meta-analysis. Clin Lab
Biophys Sin (Shanghai) 2011;43:217-25. 2013;59:1113-20.
89. Ibrahim AF, Weirauch U, Thomas M, Grunweller A, 108. Wang XW, Heegaard NH, Orum H. MicroRNAs in liver
Hartmann RK, Aigner A. MicroRNA replacement therapy disease. Gastroenterology 2012;142:1431-43.
for miR-145 and miR-33a is effi cacious in a model of colon 109. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S,
carcinoma. Cancer Res 2011;71:5214-24. Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK,
90. Yang JD, Roberts LR. Epidemiology and management Chen A, Zhou Y, Persson R, King BD, Kauppinen S,
of hepatocellular carcinoma. Infect Dis Clin North Am Levin AA, Hodges MR. Treatment of HCV infection by
2010;24:899-919, viii. targeting microRNA. N Engl J Med 2013;368:1685-94.
91. Bruix J, Sherman M. Management of hepatocellular 110. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P.
carcinoma. Hepatology 2005;42:1208-36. Modulation of hepatitis C virus RNA abundance by a
92. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA liver-specifi c MicroRNA. Science 2005;309:1577-81.
Cancer J Clin 2012;62:10-29. 111. Fukuhara T, Matsuura Y. Role of miR-122 and lipid
93. Huang XB, Li J, Zheng L, Zuo GH, Han KQ, Li HY, Liang P. metabolism in HCV infection. J Gastroenterol 2013;48:169-76.
Bioinformatics analysis reveals potential candidate drugs for 112. Bouchie A. First microRNA mimic enters clinic. Nat
HCC. Pathol Oncol Res 2013;19:251-8. Biotechnol 2013;31:577.
94. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the 113. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL,
United States. Hepatology 2002;36:S74-83. Nagorney DM. Biliary tract cancers. N Engl J Med
1999;341:1368-78.
95. Lin CL, Kao JH. Hepatitis B viral factors and clinical
outcomes of chronic hepatitis B. J Biomed Sci 2008;15:137-45. 114. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet
2014;383:2168-79.
96. Zhu Z, Zhang X, Wang G, Zheng H. Role of microRNAs in
hepatocellular carcinoma. Hepat Mon 2014;14:e18672. 115. Blechacz B, Gores GJ. Cholangiocarcinoma: advances
in pathogenesis, diagnosis, and treatment. Hepatology
97. Otsuka M, Kishikawa T, Yoshikawa T, Ohno M, 2008;48:308-21.
Takata A, Shibata C, Koike K. The role of microRNAs in 116. Olaru AV, Ghiaur G, Yamanaka S, Luvsanjav D, An F,
hepatocarcinogenesis: current knowledge and future prospects. Popescu I, Alexandrescu S, Allen S, Pawlik TM, Torbenson M,
J Gastroenterol 2014;49:173-84. Georgiades C, Roberts LR, Gores GJ, Ferguson-Smith A,
98. Hung CH, Chiu YC, Chen CH, Hu TH. MicroRNAs in Almeida MI, Calin GA, Mezey E, Selaru FM. MicroRNA
hepatocellular carcinoma: Carcinogenesis, progression, and down-regulated in human cholangiocarcinoma control cell
therapeutic target. Biomed Res Int 2014;2014:486407. cycle through multiple targets involved in the G1/S checkpoint.
99. Petrelli A, Perra A, Cora D, Sulas P, Menegon S, Manca C, Hepatology 2011;54:2089-98.
Migliore C, Kowalik MA, Ledda-Columbano GM, 117. Li L, Masica D, Ishida M, Tomuleasa C, Umegaki S,
Giordano S, Columbano A. MicroRNA/gene profi ling unveils Kalloo AN, Georgiades C, Singh VK, Khashab M, Amateau S,
early molecular changes and nuclear factor erythroid related Li Z, Okolo P, Lennon AM, Saxena P, Geschwind JF,
factor 2 (NRF2) activation in a rat model recapitulating human Schlachter T, Hong K, Pawlik TM, Canto M, Law J,
hepatocellular carcinoma (HCC). Hepatology 2014;59:228-41. Sharaiha R, Weiss CR, Thuluvath P, Goggins M, Shin EJ,
100. Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, Huang L, Li H, Peng H, Kumbhari V, Hutfl ess S, Zhou L, Mezey E,
Tan W, Wang C, Lin D. Circulating microRNAs, miR-21, Meltzer SJ, Karchin R, Selaru FM. Human bile contains
miR-122, and miR-223, in patients with hepatocellular microRNA-laden extracellular vesicles that can be used for
carcinoma or chronic hepatitis. Mol Carcinog 2011;50:136-42. cholangiocarcinoma diagnosis. Hepatology 2014;60:896-907.
101. Li J, Wang Y, Yu W, Chen J, Luo J. Expression of serum 118. Piontek K, Selaru FM. MicroRNAs in the biology
miR-221 in human hepatocellular carcinoma and its prognostic and diagnosis of cholangiocarcinoma. Semin Liver Dis
signifi cance. Biochem Biophys Res Commun 2011;406:70-3. 2015;35:55-62.

Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 3 ¦ October 15, 2015 ¦ 153